Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. BioNTech SE
  6. News
  7. Summary
    BNTX   US09075V1026

BIONTECH SE

(BNTX)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Press Release : FDA Advisory Committee Votes -4-

09/18/2021 | 03:40am EDT

upon commercialization; the ability to effectively scale our productions capabilities; and other potential difficulties.

For a discussion of these and other risks and uncertainties, see BioNTech's Annual Report as Form 20-F for the Year Ended December 31, 2020, filed with the SEC on March 30, 2021, which is available on the SEC's website at https://www.globenewswire.com/Tracker?data=I_ZXFvkayYcxAO9D6yueBZCE9jJLa-bfvTcTSmzFPiJ6q8NdZlPj3YTikIlqpietyH80zI7_mt_utzUeuh1olg== www.sec.gov. All information in this press release is as of the date of the release, and BioNTech undertakes no duty to update this information unless required by law.

CONTACTS

Pfizer:

Media Relations

Amy Rose

+1 (212) 733-7410

https://www.globenewswire.com/Tracker?data=-qM3kh6jpyGIv_grALlLNDlsz27OW_UKOqv6au-E0OrThF4H6K0QTjUxTkeUlSzNLxTsviy1o8CTweu2M1tqCRCt7ghZLVNlLtD8XokagJ0= Amy.Rose@pfizer.com

Investor Relations

Christopher Stevo

+1 (212) 733-0437

https://www.globenewswire.com/Tracker?data=iKoGOr_1gsIqHYVMK-aON-Jjbz0mPwcdebIVqGfbsdiR0R3jN0ttt5YJaJ1T02Pfih9xG6WwLZnnqYKk9djnRoZRCZUT9knAeTns4mo-fnLfyB5nQATkmUqdCO1XK87i Christopher.Stevo@pfizer.com

BioNTech:

Media Relations

Jasmina Alatovic

+49 (0)6131 9084 1513

https://www.globenewswire.com/Tracker?data=9h0Njbz-uomqOwQORh3yJB4p77U9oN0arMZ1kF_5qIYbH_U0g_KtaMPQ3I8DBkh7mRwFKhL0BV9mrx4yaGzMvofNki8wI5Y2BM0pN7WnBMA= Media@biontech.de

Investor Relations

Sylke Maas, Ph.D.

+49 (0)6131 9084 1074

https://www.globenewswire.com/Tracker?data=K-cpNFYGmggHBpUFDqxVSrzRoYJEou9msl5OUP4K9oF63FXF2mbd1qk695_EX5y2yWXoII8xGQ5xfTEHlb4Ip_0-MRpfao6fKPCS7JL6CSU= Investors@biontech.de

(END) Dow Jones Newswires

September 18, 2021 03:40 ET (07:40 GMT)

All news about BIONTECH SE
02:54pPFIZER WILL SHIP MILLIONS OF VACCINE : Trudeau
AQ
12:48pBIONTECH : Shares Rise After Data Shows Efficacy of COVID-19 Vaccine's Booster Dose
MT
11:29aGLOBAL MARKETS LIVE : Tesla, Unilever, Paypal, Elliott, Novartis...
11:26aCanada, Pfizer Strike Deal on Pediatric Vaccine Doses
DJ
11:07aEuropean ADRs Move Lower in Thursday Trading
MT
08:21aPFIZER : BioNTech Say Phase 3 Trial Data Showed Efficacy of Their COVID-19 Vaccine's Boost..
MT
08:11aMODERNA : EU regulator verdict on Moderna COVID-19 booster shot next week
RE
07:14aBIONTECH : PFIZER ANDBIONTECH ANNOUNCE PHASE 3 TRIAL DATA SHOWING HIGH EFFICACY OF A COVID..
PU
07:07aPFIZER : BioNTech Report Nearly 96% Efficacy from COVID-19 Vaccine Booster Dose
MT
06:46aPRESS RELEASE : Pfizer and BioNTech Announce Phase -4-
DJ
More news
Analyst Recommendations on BIONTECH SE
More recommendations
Financials
Sales 2021 16 684 M 19 395 M 19 395 M
Net income 2021 8 759 M 10 182 M 10 182 M
Net cash 2021 8 861 M 10 300 M 10 300 M
P/E ratio 2021 6,60x
Yield 2021 -
Capitalization 55 841 M 65 071 M 64 911 M
EV / Sales 2021 2,82x
EV / Sales 2022 2,11x
Nbr of Employees 2 500
Free-Float 87,3%
Chart BIONTECH SE
Duration : Period :
BioNTech SE Technical Analysis Chart | BNTX | US09075V1026 | MarketScreener
Technical analysis trends BIONTECH SE
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 14
Last Close Price 231,20 €
Average target price 257,50 €
Spread / Average Target 11,4%
EPS Revisions
Managers and Directors
Ugur Sahin Chief Executive Officer
Jens Holstein Chief Financial Officer
Helmut Jeggle Chairman-Supervisory Board
Özlem Türeci Chief Medical Officer
Sierk Pötting Chief Operating Officer
Sector and Competitors
1st jan.Capi. (M$)
BIONTECH SE251.28%65 071
GILEAD SCIENCES, INC.14.76%83 830
WUXI APPTEC CO., LTD.25.77%64 894
REGENERON PHARMACEUTICALS16.48%58 504
VERTEX PHARMACEUTICALS-21.52%48 121
BEIGENE, LTD.44.20%34 774